Ally Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Ally Financial’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-55,000	Closed	-$1.83M	–	121
2017 Q2	$1.83M	Hold	55,000	–	–	0.36%	81
2017 Q1	$1.76M	Hold	55,000	–	–	0.4%	87
2016 Q4	$1.99M	Buy	+55,000	New	+$2.2M	0.34%	76
2014 Q1	–	Sell	-310,000	Closed	-$12.4M	–	153
2013 Q4	$12.4M	Hold	310,000	–	–	1.32%	24
2013 Q3	$11.7M	Hold	310,000	–	–	1.28%	24
2013 Q2	$12.2M	Buy	+310,000	New	+$12.1M	1.2%	26

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ally Financial's TEVA Position: Q3 2017 in Review

Ally Financial sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 55,000 shares — an estimated $1.83M sold.

Ally Financial first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $12.4M in Q4 2013. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Ally Financial reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Ally Financial sold 55,000 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.83M.
Ally Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Ally Financial's Teva Pharmaceuticals position peaked at $12.4M in Q4 2013.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Ally Financial's 13F filing for Q3 2017, filed 13 Nov 2017.